ICU Medical, Inc. — Q1 2013 Form 10-Q
Business context and reporting period: The filing covers the three months ended March 31, 2013. ICU Medical develops, manufactures and sells medical devices for infusion therapy, critical care and oncology. It operates as one business segment.
Financial performance and position
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Total revenue | $74.3 million | $75.5 million | Down 1.6% |
| Gross profit / margin | $36.8 million / 49.5% | $35.0 million / 46.3% | Margin up 3.2 percentage points |
| Operating income / margin | $12.0 million / 16.2% | $11.4 million / 15.1% | Income up 5.6% |
| Net income | $8.7 million | $7.6 million | Up 14.3% |
| Diluted EPS | $0.58 | $0.53 | Up 9.4% |
| Operating cash flow | $10.8 million | $18.3 million | Down 41.3% |
- Gross-margin improvement reflected manufacturing efficiencies. SG&A rose to $22.9 million from $20.9 million, while R&D fell to $1.9 million from $2.7 million.
- Cash, cash equivalents and investments totaled $233.6 million at quarter-end, up from $226.2 million at December 31, 2012. Cash and cash equivalents were $154.6 million; investments were $78.9 million.
- Current assets were $334.1 million and current liabilities were $25.6 million. The balance sheet reports no interest-bearing debt; it includes a $3.3 million income tax liability.
- Capital expenditures were $5.8 million. The company reported a $7.7 million increase in cash during the quarter.
Changes and business drivers
- Domestic sales fell 7% to $52.0 million, chiefly as Hospira reduced planned Clave shipments to lower its inventory. Sales to Hospira declined 13% to $25.0 million.
- International sales rose 13% to $22.3 million, led by infusion therapy and oncology. Oncology sales overall increased 27% to $8.2 million; critical care sales fell 7% to $12.7 million, primarily due to domestic competition.
- Hospira represented 38% of revenue, down from 42% in Q1 2012, and 38% of accounts receivable at March 31. This remains a significant customer concentration.
- Foreign currency translation reduced other comprehensive income by $2.4 million, compared with a $2.1 million gain in Q1 2012.
Outlook, risks and contingencies
- Management expected modest growth in non-Hospira domestic sales, moderate international growth, modest infusion-therapy growth and oncology growth; it expected critical-care sales to decline. These are expectations, not guarantees.
- Management estimated 2013 SG&A at approximately 27% of revenue, R&D at approximately 3%, and an effective tax rate of approximately 33% including discrete items.
- Estimated 2013 capital expenditures were $30–$35 million, including planned Salt Lake City manufacturing-space and clean-room improvements and equipment, mold and IT investments. Management said existing cash, investments and expected operating cash flow should fund operations for at least 12 months.
- Key risks include reliance on Hospira and a small number of customers, customer ordering and inventory fluctuations, increased competition, execution and market acceptance of new products, foreign exchange exposure, and production and raw-material risks. The company does not hedge foreign currency exposure.
- A patent infringement case against RyMed remained pending. A jury had found infringement and patent validity; the court had yet to rule on a defense, and any damages trial would follow. The filing provides no clear value for potential damages. Management said other routine proceedings were not expected to materially affect results.
- Indemnification agreements have no stated maximum exposure, although management reported no material historical liability and did not expect one. No material risk-factor changes were reported.
Important facts for investors to verify
- Whether Hospira’s planned inventory reduction was temporary and how customer concentration and receivables develop.
- Whether gross-margin gains persist and planned capital spending delivers the expected capacity and efficiency benefits.
- Progress in oncology and international sales against critical-care competition and the company’s stated outlook.
- The outcome and possible damages in the RyMed patent litigation, plus foreign-exchange and investment-portfolio risks.